Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641201 | 0.86 | EGLN1 (0.54) | EGLN1EGLN3HPGDHIF1A | |
| SCHEMBL1642767 | 0.85 | EGLN1 (0.45) | EGLN1EGLN3HPGDMEN1KMT2A | |
| SCHEMBL1642705 | 0.84 | EGLN1 (0.48) | EGLN1EGLN3HPGDHIF1A | |
| SCHEMBL1641920 | 0.84 | EGLN1 (0.48) | EGLN1EGLN3 | |
| SCHEMBL1642807 | 0.83 | TOP2A (0.49) | EGLN1EGLN3HIF1A | |
| SCHEMBL1641131 | 0.83 | EGLN1 (0.59) | EGLN1EGLN3 | |
| SCHEMBL1641593 | 0.82 | EGLN1 (0.47) | EGLN1EGLN3HIF1A | |
| SCHEMBL1642544 | 0.82 | EGLN1 (0.46) | EGLN1EGLN3KMT2A | |
| SCHEMBL1641577 | 0.78 | HIF1A (0.45) | EGLN1EGLN3HIF1A | |
| SCHEMBL1642238 | 0.78 | EGLN3 (0.49) | EGLN1EGLN3HPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN3 3/4885HPGD 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.